End-stage Heart Failure
27
4
6
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.7%
1 terminated out of 27 trials
90.0%
+3.5% vs benchmark
11%
3 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (27)
Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure
Echocardiographic Assessment of the Effect of Impella on Biventricular Function
LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients
Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
Donor Circadian Rhythm and Its Correlation With Prognosis After Heart Transplantation
AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support
Whole Heart Radiotherapy for End-stage Heart Failure
Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
Carmat TAH Early Feasibility Study
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
Ventricular Tachycardia Ablation in LVAD Patients
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
Corheart 6 LVAS LTFU
Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device
Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)